TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27575599

Group type: EXPERIMENTAL
Intervention: Individualised audit and feedback (A&F) intervention
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Individualised graphical A&F plus written behaviour change message
Number of subjects: 795

Group type: COMPARATOR
Intervention: Control group (no A&F intervention)
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: A&F with health board comparator
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: A&F at 0 and 6 months
Number of subjects: 795
Study: 24704290

Group type: EXPERIMENTAL
Intervention: 20 ml aspiration
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 10 ml aspiration
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0 ml aspiration (no aspiration)
Number of subjects: 100
Study: 22140197

Group type: EXPERIMENTAL
Intervention: Robotic-assisted gait training (RAGT) using Lokomat
Number of subjects: 67

Group type: COMPARATOR
Intervention: Over-ground walking training
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both groups (RAGT and over-ground walking training)
Number of subjects: 67
Study: 20571374

Group type: EXPERIMENTAL
Intervention: Structured computer course on Internet health information retrieval
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not attending the program)
Number of subjects: 12
Study: 17885258

Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 7329

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 7329
Study: 16036198

Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian multi-needle intervention (LOMNI)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Step-up ovulation induction treatment with recombinant follicle-stimulating hormone followed by intrauterine insemination for three cycles
Number of subjects: 35
Study: 12506332

Group type: EXPERIMENTAL
Intervention: Digoxin level determinations
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Routine monitoring of digoxin levels
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Inappropriate digoxin level determinations
Number of subjects: 210
Study: 9926183

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg i.v. before propofol (2 mg/kg) induction (Group A)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Mixture of propofol and metoclopramide (Group B)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Metoclopramide i.v. with rubber tourniquet for 1 min before propofol (Group C)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg (Group D)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Saline (Group E)
Number of subjects: 175
Study: 7770284

Group type: EXPERIMENTAL
Intervention: r‐HuEPO (100 U/kg/d, 5 days per week)
Number of subjects: 157
Study: 2333803

Group type: EXPERIMENTAL
Intervention: Affective/cognitive empathy training program (4 sessions of 1.5 hours each)
Number of subjects: 24
Study: 340332

Group type: EXPERIMENTAL
Intervention: Cimetidine plus antacid
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Cimetidine plus dummy antacid
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo tablet plus antacid
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Antacids
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 240
Study: 30548106

Group type: COMPARATOR
Intervention: PB-SCS (paresthesia-based stimulation)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SP-SCS (subperception-based stimulation) - burst program
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SP-SCS (subperception-based stimulation) - 1 kHz program
Number of subjects: 28
Study: 28832739

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.03% eye drops t.i.d.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sodium cromoglycate 4% eye drops t.i.d.
Number of subjects: 16
Study: 25461822

Group type: EXPERIMENTAL
Intervention: Motor Learning (ML) alone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Robotics plus Motor Learning (ML)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) plus Motor Learning (ML)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 39
Study: 23365053

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine 25 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intranasal midazolam 2 mg
Number of subjects: 30
Study: 21069378

Group type: EXPERIMENTAL
Intervention: Endurance athletes (EG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 20
Study: 19584603

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) during treatment
Number of subjects: 10000000

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) during survivorship
Number of subjects: 10000000

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) during palliative care
Number of subjects: 10000000

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 10000000
Study: 17969813

Group type: EXPERIMENTAL
Intervention: Taxol + Cisplatin (Tax + Cis)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Cyclophosphamide + Etoposide + Carboplatin (CEP)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Neuroendocrine differentiation
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: No neuroendocrine differentiation
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Tax + Cis group
Number of subjects: 85

Group type: COMPARATOR
Intervention: CEP group
Number of subjects: 85
Study: 15034827

Group type: EXPERIMENTAL
Intervention: New cell-cultured smallpox vaccine
Number of subjects: 350

Group type: COMPARATOR
Intervention: Live vaccinia virus vaccine
Number of subjects: 350
Study: 11685164

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin 70 U/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dalteparin 60 IU/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both unfractionated heparin and dalteparin
Number of subjects: 40
Study: 9922821

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan 6 mg
Number of subjects: 186

Group type: COMPARATOR
Intervention: Customary treatment
Number of subjects: 186
Study: 7998416

Group type: EXPERIMENTAL
Intervention: B subunit-whole cell cholera vaccine (B-WC), 2 or 3 doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: B subunit-whole cell cholera vaccine (B-WC), 2 doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New B subunit-whole cell cholera vaccine (recombinant B subunit)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (previously unvaccinated)
Number of subjects: 0
Study: 3263243

Group type: EXPERIMENTAL
Intervention: High-dose corticosteroids (HDC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Infused saline (Control)
Number of subjects: 30
Study: 29756459

Group type: COMPARATOR
Intervention: Expiratory muscle training
Number of subjects: 31
Study: 27506739

Group type: EXPERIMENTAL
Intervention: Interval-walking (IW)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous walking (CW)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 10
Study: 25609264

Group type: EXPERIMENTAL
Intervention: n-3 PUFAs enriched intravenous fat emulsion (IVFE)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group receiving a lipid emulsion comprised of soybean oil and MCTs
Number of subjects: 99
Study: 23875551

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group therapy (4 sessions)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 20177843

Group type: EXPERIMENTAL
Intervention: Mindfulness training group
Number of subjects: 71

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 71
Study: 18379396

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg for 4 weeks, then maintained or titrated to 5 or 20 mg at weeks 4 and 8
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 418

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study: 15685244

Group type: EXPERIMENTAL
Intervention: 74 Gy group
Number of subjects: 126

Group type: COMPARATOR
Intervention: 64 Gy group
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 1.0 cm margin group
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 1.5 cm margin group
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 126
Study: 12889591

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 0
Study: 10574413

Group type: EXPERIMENTAL
Intervention: Irbesartan monotherapy started at 75 mg and titrated to 300 mg
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Irbesartan or irbesartan/hydrochlorothiazide
Number of subjects: 1006
Study: 8921578

Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg initially, 1 mg every four hours for 24 hours)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Somatostatin (250 micrograms bolus and continuous infusion of 250 micrograms/h for 24 hours)
Number of subjects: 72
Study: 2060544

Group type: EXPERIMENTAL
Intervention: Amitriptyline (37.5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Trazodone (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6834243

Group type: EXPERIMENTAL
Intervention: Consistent control over shock
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: No control over shock
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Intermittent control over shock
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: High-stress conditions (consistent, no control, intermittent)
Number of subjects: 96
Study: 30545649

Group type: EXPERIMENTAL
Intervention: NuCare intervention (self-directed workbook) for 6 weeks
Number of subjects: 89

Group type: COMPARATOR
Intervention: Usual care (control condition)
Number of subjects: 89
Study: 30166329

Group type: EXPERIMENTAL
Intervention: eBEACOPP (escalated doses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone)
Number of subjects: 1005
Study: 26218231

Group type: EXPERIMENTAL
Intervention: Strength Training Group (STG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 30
Study: 24435546

Group type: EXPERIMENTAL
Intervention: Calcium-enriched mixture (CEM) cement
Number of subjects: 51

Group type: COMPARATOR
Intervention: Electrosurgery and zinc oxide eugenol (ES/ZOE)
Number of subjects: 51
Study: 22452529

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 4306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4306
Study: 21166630

Group type: EXPERIMENTAL
Intervention: QVA149 (indacaterol/NVA237) 600/100 microg
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: QVA149 (indacaterol/NVA237) 300/100 microg
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: QVA149 (indacaterol/NVA237) 150/100 microg
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: QVA149 (indacaterol/NVA237)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 257
Study: 18046975

Group type: EXPERIMENTAL
Intervention: Zofenopril 30-60 mg once daily
Number of subjects: 303

Group type: COMPARATOR
Intervention: Amlodipine 5-10 mg once daily
Number of subjects: 303
Study: 17592372

Group type: EXPERIMENTAL
Intervention: Telephone counseling (IG1)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Written information (IG2)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Personal telephone counseling (IG3)
Number of subjects: 183

Group type: COMPARATOR
Intervention: No counseling (IG0)
Number of subjects: 183
Study: 12690593

Group type: EXPERIMENTAL
Intervention: UFOV training of visual processing speed, divided attention, and selective attention
Number of subjects: 97

Group type: COMPARATOR
Intervention: Traditional computerized visuoperception retraining
Number of subjects: 97
Study: 11094308

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) alpha‐2b at a dose of 20 MU/m2/day, 5 days per week for one month, followed by 10 MU/m2 TIW, up to one complete year of therapy
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 1000
Study: 9186075

Group type: EXPERIMENTAL
Intervention: Quality of Well‐Being (QWB) scale
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: Symptom Checklist‐90R (SCL‐90R)
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: Patient Symptom Form
Number of subjects: 1284
Study: 1338896

Group type: EXPERIMENTAL
Intervention: Low-fat diet intervention
Number of subjects: 905

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 905
Study: 2413300

Group type: EXPERIMENTAL
Intervention: Intravenous trimazosin (100 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral trimazosin (200 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 6
Study: 31185369

Group type: EXPERIMENTAL
Intervention: Loving-kindness meditation (LKM)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 142
Study: 28957806

Group type: EXPERIMENTAL
Intervention: Bladder flap
Number of subjects: 208

Group type: COMPARATOR
Intervention: Omission of bladder flap
Number of subjects: 208
Study: 27733571

Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: SC IFN‐β‐1a 44 μg
Number of subjects: 0
Study: 24959193

Group type: EXPERIMENTAL
Intervention: Shen-Zhi-Ling oral liquid (SZL)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo granules
Number of subjects: 98
Study: 22399518

Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg daily for 6 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 20726258

Group type: EXPERIMENTAL
Intervention: 1 dose booster of HepB
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 3 dose booster of HepB
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 4 different types of HepB (5 microg HepB-Y, 10 microg HepB-Y, 10 microg HepB-CHO, 10 microg HepB-HY) after 3 doses revaccination
Number of subjects: 103
Study: 17681993

Group type: EXPERIMENTAL
Intervention: Active treatments for smoking cessation (specific treatments not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compliance-predictive covariates used to model probability of membership in principal strata
Number of subjects: 0
Study: 17849193

Group type: EXPERIMENTAL
Intervention: Phonemic Awareness, Picture Vocabulary, Rapid Naming, Single Word Reading
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Phonemic Awareness, Picture Vocabulary, Rapid Naming (excluding Single Word Reading)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Predicting which students would be in the bottom 15% and 30% of actual first grade WJBR
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Predicting the bottom 15% and 30% of actual third grade WJBR outcomes
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Predicting the bottom 15% and 30% of actual eighth grade WJBR scores
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: New tests of the same four predictor domains administered to N=500 late kindergartners through third graders
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Using the same regression weights from Study 1
Number of subjects: 220
Study: 12448933

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 62

Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 62
Study: 10410494

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8542861

Group type: EXPERIMENTAL
Intervention: nalbuphine mixed with lignocaine (2 mg mL‐1)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: diluted nalbuphine (2 mg mL‐1)
Number of subjects: 66

Group type: COMPARATOR
Intervention: saline
Number of subjects: 66
Study: 1930343

Group type: EXPERIMENTAL
Intervention: Midazolam (7.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6885176

Group type: EXPERIMENTAL
Intervention: Erythromycin lactobionate (1 g in 0.9% NaCl) infused in 120 ml
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Erythromycin lactobionate (1 g in 0.9% NaCl) infused in 250 ml
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl) infused in 120 ml
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl) infused in 250 ml
Number of subjects: 40
Study: 30738409

Group type: EXPERIMENTAL
Intervention: Arterial oxygenation at 150 mm Hg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arterial oxygenation at 200 mm Hg
Number of subjects: 0
Study: 30091666

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg/day) with resistance training
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo with resistance training
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg/day) without resistance training
Number of subjects: 58
Study: 26608714

Group type: EXPERIMENTAL
Intervention: Paralyzed faces (smiling)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Paralyzed faces (in repose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal faces (smiling and in repose)
Number of subjects: 60
Study: 24176066

Group type: EXPERIMENTAL
Intervention: New-onset atrial fibrillation (AF) after PCI
Number of subjects: 3681
Study: 22395762

Group type: EXPERIMENTAL
Intervention: Multicomponent psychological intervention (milieu therapy interventions and music therapy) for 6 months
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard occupational therapy
Number of subjects: 49
Study: 19103988

Group type: EXPERIMENTAL
Intervention: Vein bypass surgery
Number of subjects: 1404
Study: 16740522

Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Counseling intervention
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Video and counseling intervention
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study: 16283867

Group type: EXPERIMENTAL
Intervention: recombinant human platelet-derived growth factor (rhPDGF)
Number of subjects: 24998
Study: 12197594

Group type: EXPERIMENTAL
Intervention: Lowering reperfusate PO2 (PO2=200‐250 mmHg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hyperoxic reperfusion (PO2=450‐550 mmHg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hyperoxic reperfusion with diltiazem (0.5 microg/kg)
Number of subjects: 30
Study: 9793313

Group type: EXPERIMENTAL
Intervention: Budesonide 0.8 mg/day
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Budesonide 1.2 mg/day
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Budesonide 2.4 mg/day
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Budesonide 3.2 mg/day
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Prednisone 10 mg/day
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Prednisone 40 mg/day
Number of subjects: 78
Study: 7906300

Group type: EXPERIMENTAL
Intervention: recombinant gp160 (rgp160)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Addition of zidovudine for 2 weeks after each immunization
Number of subjects: 40
Study: 2777592

Group type: EXPERIMENTAL
Intervention: Betadine‐R solution
Number of subjects: 540

Group type: COMPARATOR
Intervention: NaCl
Number of subjects: 540
Study: 1206393

Group type: EXPERIMENTAL
Intervention: L-tryptophan (1.5 g or 8 g daily for 30 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (30-day period after treatment)
Number of subjects: 12
Study: 31165653

Group type: EXPERIMENTAL
Intervention: exercise and nutrition counseling plus the MORE intervention
Number of subjects: 51

Group type: COMPARATOR
Intervention: exercise and nutrition counseling
Number of subjects: 51
Study: 27890885

Group type: EXPERIMENTAL
Intervention: Administration Timing Simplification Protocol (ATSP)
Number of subjects: 210
Study: 25056158

Group type: EXPERIMENTAL
Intervention: Holter monitor ECG recording
Number of subjects: 1036
Study: 23263204

Group type: EXPERIMENTAL
Intervention: Inhalation anaesthesia with fentanyl (Group I)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Inhalation anaesthesia with remifentanil (Group II)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intravenous anaesthesia (TIVA) with propofol and remifentanil (Group III)
Number of subjects: 90
Study: 21781314

Group type: EXPERIMENTAL
Intervention: Trans-obturator tape (TOT)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 199
Study: 19243712

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN)
Number of subjects: 1613

Group type: EXPERIMENTAL
Intervention: Extended-release niacin/laropiprant (ERN/LRPT) combination
Number of subjects: 1613
Study: 16677158

Group type: EXPERIMENTAL
Intervention: Pantoprazole infusion (80 mg intravenous bolus followed by an infusion at a rate of 8 mg per hour for 72 hours)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Pantoprazole infusion
Number of subjects: 203
Study: 15290416

Group type: COMPARATOR
Intervention: 0% N(2)O (N0 group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 50% N(2)O (N50 group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 66% N(2)O (N66 group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Latency of MEP
Number of subjects: 60
Study: 16036266

Group type: EXPERIMENTAL
Intervention: Telephone-based counseling
Number of subjects: 1329

Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 1329
Study: 10341332

Group type: EXPERIMENTAL
Intervention: GBV‐C/HGV RNA detection by PCR
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HGV antibodies detection by serological assay
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Contact with GBV‐C/HGV virus
Number of subjects: 100
Study: 7574743

Group type: EXPERIMENTAL
Intervention: HAI chemotherapy with 5-FU 500 mg/day for 6 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no regional chemotherapy)
Number of subjects: 19
Study: 1973865

Group type: EXPERIMENTAL
Intervention: Astemizole 10-mg tablets
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 44